PubMed Central
Cure8 research brief
Why This Matters
A coordinated national research network can accelerate studies that matter to people with IBD—like tracking real-world disease patterns, testing diet and psychosocial approaches, improving monitoring with biomarkers and imaging, and exploring microbiome and AI tools that might eventually influence care.
Who Should Pay Attention
Researchers and clinicians involved in IBD epidemiology, translational science, and care delivery; patients and advocates interested in registry-based research, diet/microbiome studies, and monitoring strategies; funders and health systems planning collaborative research infrastructure.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthMetadata only
What To Know
This article reviews the Israeli IBD Research Nucleus (IIRN), a national collaborative consortium linking five tertiary IBD centers in Israel and supported by the Helmsley Charitable Trust.
The review summarizes a decade of IIRN activities (2015–2025), including a population-based registry (epi-IIRN), prospective Crohn's disease cohorts, integration of imaging and capsule endoscopy, biomarker and therapeutic-drug-monitoring work, microbiome and transcriptomic translational studies, diet and psychosocial intervention research, and initial AI applications for image/report interpretation.
The paper emphasizes how shared infrastructure enabled epidemiology, longitudinal cohort studies, translational research, and multidisciplinary care programs, and it reflects on practical challenges and lessons for building similar national research consortia.
The description is drawn from the article abstract and full text as provided; this is a narrative review of the consortium's structure, outputs, and lessons rather than a single interventional trial.
Keep In Mind
This is a narrative review of the IIRN's decade of activity (2015–2025) summarizing published outputs and program development. It describes infrastructure, cohorts, and exploratory research rather than reporting results from a single randomized trial; findings should be interpreted as summaries of the consortium's work and outputs.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationPubMed Central
JournalTher Adv Gastroenterol
AuthorsDotan, Iris, Ben-Horin, Shomron, Schwartz, Doron +7 more
Indexed viaPubMed Central
Source typeResearch repository record
PublishedJul 13, 2026, 12:00 AM
Content availableMetadata only
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Machine Learning Model Identifies Gut Biomarkers That May Help Diagnose IBD Patients
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.
Is There a Blood Test That Distinguishes Crohn's Disease From UC? - HealthCentral
Distinguishing Crohn’s from ulcerative colitis can be hard and often requires invasive tests. A reliable blood test would speed diagnosis and help patients start the right treatments sooner. This study is an early step...
Microbiota Dynamics in Crohn's Disease Recurrence - Docwire News
Postoperative recurrence after ileal resection is common in Crohn’s disease; understanding microbial changes linked to recurrence could help explain mechanisms and guide future biomarker development.